Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kalaris Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Kalaris Therapeutics, Inc.’s stock price such as:

• Kalaris Therapeutics, Inc.’s current stock price and volume
• Why Kalaris Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for KLRS from analysts
• KLRS’s stock price momentum as measured by its relative strength

About Kalaris Therapeutics, Inc. (KLRS)

Before we jump into Kalaris Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Want to learn more about Kalaris Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc.’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Kalaris Therapeutics, Inc.’s stock price was $6.240.

Kalaris Therapeutics, Inc. is down 3.11% from its previous closing price of $6.440.

During the last market session, Kalaris Therapeutics, Inc.’s stock traded between $5.660 and $6.540. Currently, there are approximately 18.70 million shares outstanding for Kalaris Therapeutics, Inc..

Kalaris Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Kalaris Therapeutics, Inc. Stock Price History

Kalaris Therapeutics, Inc.’s (KLRS) price is currently up 24.06% so far this month.

During the month of November, Kalaris Therapeutics, Inc.’s stock price has reached a high of $7.140 and a low of $4.502.

Over the last year, Kalaris Therapeutics, Inc. has hit prices as high as $12.900 and as low as $2.140.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kalaris Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there was 1 analyst who downgraded Kalaris Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Kalaris Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kalaris Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kalaris Therapeutics, Inc. (KLRS) by visiting AAII Stock Evaluator.

Relative Price Strength of Kalaris Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Kalaris Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Kalaris Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kalaris Therapeutics, Inc. Stock Price: Bottom Line

As of November 28, 2025, Kalaris Therapeutics, Inc.’s stock price is $6.240, which is down 3.11% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kalaris Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.